Search

Your search keyword '"Webb I"' showing total 286 results
Start Over Author "Webb I"
286 results on '"Webb I"'

4. Improved phenotyping of cardiogenic shock after out-of-hospital cardiac arrest

Author

Abd Razak, M, primary, Roy, R, additional, Parczewska, A, additional, Mcgarvey, M, additional, Lam, L, additional, To-Dang, B, additional, Jaguszewski, M, additional, Webb, I, additional, Dworakowski, R, additional, Melikian, N, additional, Shah, A, additional, Maccarthy, P, additional, Gruchala, M, additional, Byrne, J, additional, and Pareek, N, additional

Published
2023
Full Text
View/download PDF

5. Coronary flow reserve predicts response to anti-ischaemic therapy in patients with angina with non-obstructive coronary arteries

Author

Sinha, A, primary, Rahman, H, additional, Dutta, U, additional, Demir, O, additional, De Silva, K, additional, Clapp, B, additional, Webb, I, additional, Gulati, A, additional, Pinho, P, additional, Ellis, H, additional, Chiribiri, A, additional, Shah, A, additional, Marber, M, additional, Webb, A, additional, and Perera, D, additional

Published
2023
Full Text
View/download PDF

6. The left main coronary artery (LMCA) physiology study: comprehensive clinical haemodynamic evaluation of physiology and pathophysiology

Author

Demir, O M, primary, Sinha, A, additional, Rahman, H, additional, Scannell, C, additional, Alfakih, K, additional, O'gallagher, K, additional, Ryan, M, additional, Li Kam Wa, M, additional, Ellis, H, additional, Webb, I, additional, Melikian, N, additional, De Silva, K, additional, Chiribiri, A, additional, Plein, S, additional, and Perera, D, additional

Published
2023
Full Text
View/download PDF

7. A machine learning algorithm to predict a culprit lesion after out of hospital cardiac arrest

Author

Roy, R, primary, Abdrazak, M, additional, Smith, M, additional, Frohmaier, C, additional, Kordis, P, additional, Sunderland, N, additional, Webb, I, additional, Dworakowski, R, additional, Melikian, N, additional, Johnson, T W, additional, Noc, M, additional, Byrne, J, additional, Maccarthy, P, additional, Shah, A M, additional, and Pareek, N, additional

Published
2023
Full Text
View/download PDF

10. The effect of ethnicity and social deprivation on outcomes after resuscitated out-of-hospital cardiac arrest

Author

Roy, R, primary, Kanyal, R, additional, Abd Razak, M, additional, To-Dang, B, additional, Chotai, S, additional, Abu-Own, H, additional, Cannata, A, additional, Dworakowski, R, additional, Webb, I, additional, Pareek, M, additional, Shah, A M, additional, Maccarthy, P, additional, Byrne, J, additional, Melikian, N, additional, and Pareek, N, additional

Published
2023
Full Text
View/download PDF

20. Social class and the tragic vision in Hardy's novels : an examination of Lucien Goldmann's genetic structuralism

Author

Webb, I.

Subjects
800, Literature
Abstract

There has been very little substantive empirical work in the field of the sociology of literature, and, with a few notable exceptions# much of the published work centres around theoretical issues. Lucien Goldmann was a theorist who rigorously attempted to apply his own theories about literary explanation to actual texts. The thesis I am presenting contains an evaluation of Goldmann's theoretical work and an assessment of his empirical research, particularly that relating to seventeenth century French literature. The fundamental hypothesis underlying this research is the idea that literary works are the expressions of a particular view of the world, or a world vision# belonging to the author# which can only be explained by reference to the social class of that author and the position of that class in the economic and social structure. In his work on the playwright Racine and the philosopher Pascal, Goldmann is specifically interested in the type of vision he refers to as the tragic vision, the genesis of which, he maintain~ is to be found in the ideological structure of a religious movement known as Jansenism, which itself is explicable·only by reference to the social class of members of the Jansenist group - i.e. the 'noblesse de robe',which during this period underwent a decline in economic1 political and social status. The thesis concentrates on the notion of the tragic vision being the expression of the world view of members of'a declining social classl and if Goldmann's theory is valid at alll it should be applicable to literary forms other than that of the classical drama. The novels of Thomas Hardy were selected to provide an empirical test of Goldman's genetic-structuralist method. Following Goldman's work on Racine an immanent analysis of the novels in chronological order is undertaken using Goldman's own criteria of tragedy but also referring to other traditional literary critical definitions and forms of tragedy. Having established the presence of a tragic vision in Hardy's novels and elicited the components of that vision the argument then proceeds to a consideration of Hardy's social class, of origin - i.e. the rural lower middle-class - and to the ideology of the members of that class and finally to its situation during the nineteenth century. Other factors such as Hardy's personal biography and his social mobility, and the conditions of literary production, are also examined to assess their significance as mediations between the social class of the author and the literary work itself

Published
1981

22. The effect of HIFU-relevant rates of heating on the growth and dissolution of nuclei available for inertial cavitation

Author

Webb, I, Arora, M, Collin, J, Payne, S, Roy, R, and Coussios, C

Abstract

A theoretical model is sought to explain recent experimental results which have shown the sudden onset of inertial cavitation after a significant period of ultrasound insonation. It is thought that there initially exists a population of bubbles with sub-optimal radii for inertial cavitation, which grow during the insonation period to become nuclei within the optimal size range to cavitate inertially. Rectified diffusion during bubble oscillation, and the changes in the bubble nucleation environment and their subsequent dynamics caused by ultrasonic heating, are amongst the mechanisms that could be responsible for nuclei growth. In this work, the effects of elevating the temperature of the medium surrounding a bubble, resulting in higher vapour pressures and decreased solubility of gas in the bulk medium, is investigated. A single bubble model is formulated by coupling a numerical solution of the mass diffusion PDE and the Rayleigh-Plesset Equation, taking into account temperature dependence of surface tension, vapour pressure, Henry’s constant and diffusion coefficient. It is shown that an increase in the temperature at HIFU-relevant heating rates is on its own not sufficient to increase the radii of sub-optimal bubbles into the optimal range for inertial cavitation to take place.

Published
2019

24. Long-term outcomes in surgically ineligible patients managed with percutaneous coronary revascularization or medical therapy.

Author

Melikian N., Dworakowski R., MacCarthy P., Webb I., Byrne J., Shah A., Danson E.J.F., Sapontis J., Kaura A., Hill J.M., Melikian N., Dworakowski R., MacCarthy P., Webb I., Byrne J., Shah A., Danson E.J.F., Sapontis J., Kaura A., and Hill J.M.

Abstract

The objective of the study was to report clinical outcomes of patients unsuitable for surgical coronary revascularization (CABG) treated with percutaneous revascularization (PCI) or medical therapy alone (MT). The decision to revascularize patients referred for CABG but who are unsuitable should be made at Heart Team meetings. The clinical outcomes in this important patient subset are not known, and while cases are considered individually, these decisions are not guided by robust data. Clinical data were analyzed for patients referred to the Heart Team for consideration of CABG over a 4-year period in a UK tertiary referral center. Outcome data for those managed with urgent PCI or MT were considered over a further 3-year period. 133 patients were treated with PCI and 117 with MT. MACE at 30 days were no different between groups (MT 10.3% versus PCI 12.2%); however, at 1 year MACE were higher in the MT group (MT 39.3% versus PCI 26.7%, P < 0.01). Log rank for MACE-free survival to 1 and 3 years was significantly lower in the MT group [HR 1.77 (0.60-1.11); P < 0.001]. Residual SYNTAX was an independent predictor of death. MT [OR 1.75 (1.03-2.99); P = 0.04] and a residual SYNTAX score [OR 6.45 (2.53-16.45); P < 0.001] were independent predictors of MACE at 1 year in the whole group. Our data reveal better outcomes in patients treated with PCI over MT at 1-3 years in CABG-ineligible patients. Patients without complete revascularization have worse outcomes.Copyright © 2018, Japanese Association of Cardiovascular Intervention and Therapeutics.

Published
2019

28. Cardiopoietic cell therapy for advanced ischemic heart failure : results at 39 weeks of the prospective, randomized, double blind, sham-controlled CHART-1 clinical trial

Author

Bartunek, Jozef, Terzic, Andre, Davison, Beth A, Filippatos, Gerasimos S, Radovanovic, Slavica, Beleslin, Branko, Merkely, Bela, Musialek, Piotr, Wojakowski, Wojciech, Andreka, Peter, Horvath, Ivan G, Katz, Amos, Dolatabadi, Dariouch, El Nakadi, Badih, Arandjelovic, Aleksandra, Edes, Istvan, Seferovic, Petar M, Obradovic, Slobodan, Vanderheyden, Marc, Jagic, Nikola, Petrov, Ivo, Atar, Shaul, Halabi, Majdi, Gelev, Valeri L, Shochat, Michael K, Kasprzak, Jaroslaw D, Sanz Ruiz, Ricardo, Heyndrickx, Guy R, Nyolczas, Noémi, Legrand, Victor, Guédès, Antoine, Heyse, Alex, Moccetti, Tiziano, Fernandez Aviles, Francisco, Jimenez Quevedo, Pilar, Bayes Genis, Antoni, Hernandez Garcia, Jose Maria, Ribichini, Flavio, Gruchala, Marcin, Waldman, Scott A, Teerlink, John R, Gersh, Bernard J, Povsic, Thomas J, Henry, Timothy D, Metra, Marco, Hajjar, Roger J, Tendera, Michal, Behfar, Atta, Alexandre, Bertrand, Seron, Aymeric, Stough, Wendy Gattis, Sherman, Warren, Cotter, Gad, Wijns, W. i. l. l. i. a. m. Collaborators Clinical investigators, Dens, sites Belgium: Ziekenhuis Oost Limburg: J., Dupont, M., Mullens, W., Janssens, M., Dolatabadi, Hoˆpital Civil de Charleroi: D., De Bruyne, Y., Lalmand, J., Dubois, P., El Nakadi, B., Aminian, A., De Vuyst, E., Gurnet, P., Gujic, M., Blankoff, I., Guedes, CHU Mont Godinne UCL: A., Gabriel, L., Seldrum, S., Doyen, C., Andre´, M., Heyse, AZ Glorieux: A., Van Durme, F., Verschuere, J., Legrand, Domaine Universitaire du Sart Tilman: V., Gach, O., D’Orio, V., Davin, L., Lancellotti, P., Baudoux, E., Ancion, A., Dulgheru, R., Vanderheyden, OLV Ziekenhuis Aalst – Cardiologie: M., Bartunek, J., Wijns, W., Verstreken, S., Penicka, . M., Gelev, P. Meeus Bulgaria: Tokuda Hospital Sofia: V., Zheleva Kichukova, I., Parapunova, R., Melamed, R., Sardovski, S., Radev, O., Yordanov, A., Radinov, A., Nenov, D., Amine, I., Petrov, City Hospital Clinic Cardiology Center: I., Kichukov, K., Nikitasov, L., Stankov, Z., Stoyanov, H., Tasheva Dimitrova, I., Angelova, M., Dimitrov, E., Minchev, M., Garvanski, I., Botev, C., Polomski, P., Alexandrovska University Hospital, Vassilev, Sofia: D., Karamfiloff, K., Tarnovska Kadreva, R., Vladimirova, L., Dimitrov, G., Hadzhiev, E., Tzvetkova, G., Andreka, . M. Atanasova Hungary: Gottsegen Gyo¨ rgy Orszagos Kardiologiai Inte´zet: P., Fontos, G., Fabian, J., Csepregi, A., Uzonyi, G., Gelei, A., Edes, Debreceni Egyetem Orvos e´s Ege´szse´gtudomanyi Centrum Altalanos Orvostudomanyi Kar Kardiologia Inte´zet: I., Balogh, L., Vajda, G., Darago, A., Gergely, S., Fulop, T., Jenei, C., Horvath, Pe´csi Tudomanyegyetem Klinikai Ko¨zpont Szıvgyogyaszati Klinika: I., Magyari, B., Nagy, A., Cziraki, A., Faludi, R., Kittka, B., Alizadeh, H., Merkely, Semmelweis Egyetem Varosmajori Szıv e´s Ergyogyaszati Klinika: B., Geller, L., Farkas, P., Szombath, G., Foldes, G., Skopal, J., Kovacs, A., Kosztin, A., Gara, E., Sydo, N., Nyolczas, MH Ege´szse´gu¨gyi Ko¨zpont Kardiologiai Osztaly: N., Kerecsen, G., Korda, A., Kiss, . M., Borsanyi, T., Polgar, B., Muk, B., Sharif, Z. Bari Ireland: HRB Clinical Research Facility: F., Atar, Y. M. Smyth Israel:Western Galilee Hospital: S., Shturman, A., Akria, L., Kilimnik, M., Brezins, M., Halabi, Ziv Medical Center: M., Dally, N., Goldberg, A., Aehab, K., Rosenfeld, I., Levinas, T., Saleem, D., Katz, Barzilai Medical Center: A., Plaev, T., Drogenikov, T., Nemetz, A., Barshay, Y., Jafari, J., Orlov, I., Nazareth Hospital EMMS: M. Omory, N. Kogan Nielsen, Shochat, Hillel Yaffe Medical Center: M., Shotan, A., Frimerman, A., Meisel, S., Asif, A., Sofer, O., Blondheim, D. S., Vazan, A., Metra, L. Arobov Italy: A. O. Spedali Civili di Brescia: M., Bonadei, I., Inama, L., Chiari, E., Lombardi, C., Magatelli, M., Russo, D., Lazzarini, V., Carubelli, V., Vassanelli, AOUI Verona – Borgo Trento Hospital: C., Ribichini, Flavio Luciano, Bergamini, C., Krampera, Mauro, Cicoria, M. A., Zanolla, L., Dalla Mura, D., Gambaro, A., Rossi, A., Pesarini Poland: Jagiellonian University Department of Cardiac, G., Musialek, Vascular Diseases at John Paul II Hospital in Krakow: P., Mazurek, A., Drabik, L., Ka˛dzielski, A., Walter, Z., Dzieciuch Rojek, M., Rubis, P., Plazak, . W., Tekieli, L., Podolec, J., Orczyk, W., Sutor, U., Zmudka, K., Olszowska, M., Podolec, P., Gruchala, Uniwersyteckie Centrum Kliniczne: M., Ciecwierz, D., Mielczarek, M., Burakowski, S., Chmielecki, M., Zielinska, M., Frankiewicz, A., Wdowczyk, J., Stopczynska, I., Bellwon, J., Mosakowska, K., Nadolna, R., Wroblewska, J., Rozmyslowska, M., Rynkiewicz, M., Marciniak, I., Raczak, G., Tarnawska, M., Taszner, M., Kasprzak, Bieganski Hospital: J., Plewka, M., Fiutowska, D., Rechcinski, T., Lipiec, P., Sobczak, M., Weijner Mik, P., Wraga, M., Krecki, R., Markiewicz, M., Haval Qawoq, D., Wojakowski, Gornosla˛skie Centrum Medyczne Sla˛skie j. Akademii Medycznej: W., Ciosek, J., Dworowy, S., Gaszewska Zurek, E., Ochala, A., Cybulski, W., Jadczyk, T., Wanha, W., Parma, Z., Kozlowski, M., Dzierzak, M., Markiewicz Serbia: Clinical Hospital Center Zvezdara, M., Arandjelovic, Cardiology Clinic: A., Sekularac, N., Boljevic, D., Bogdanovic, A., Zivkovic, S., Cvetinovic, N., Loncar, G., Clinical Centre of Serbia, Beleslin, Cardiology Clinic: B., Nedeljkovic, M., Trifunovic, D., Giga, V., Banovic, M., Nedeljkovic, I., Stepanovic, J., Vukcevic, V., Djordjevic Dikic, A., Dobric, M., Obrenovic Kircanski, B., Seferovic, Cardiology Clinic: P., Orlic, D., Tesic, M., Petrovic, O., Milinkovic, I., Simeunovic, D., Jagic, Clinical Center of Kragujevac: N., Tasic, M., Nikolic, D., Miloradovic, V., Djurdjevic, P., Sreckovic, M., Zornic, N., Clinical Hospital Center Bezanijska Kosa, Radovanovic, Cardiology Department: S., Saric, J., Hinic, S., Djokovic, A., Ðordevic, S., Bisenic, V., Markovic, O., Stamenkovic, S., Malenkovic, V., Tresnjak, J., Misic, G., Cotra, D., Tomovic, L., Vuckovic, V., Clinic of Emergency Internal Medicine, Obradovic, Military Medical Academy: S., Jovic, Z., Vukotic, S., Markovic, D., Djenic, N., Ristic Andjelkov, A., Bayes Genis, D. Ljubinka Spain: Hospital Universitario Germans Trias I. Pujol: A., Rodriguez Leor, O., Labata, C., Vallejo, N., Ferrer, E., Batlle, M., Fernandez Aviles, Hospital General Universitario Gregorio Mara~non: F., Sanz Ruiz, R., Casado, A., Loughlin, G., Zatarain, E., Anguita, J., Ferna ndez Santos, M. E., Pascual, C., Bermejo, J., Hernandez Garcia, Hospital Clinico Universitario Virgen de la Victoria: J. M., Jimenez Navarro, M., Dominguez, A., Carrasco, F., Mu~noz, A., Garcia Pinilla, J. M., Ruiz, J., Queipo de Llano, M. P., Hernandez, A., Fernandez, A., Jimenez Quevedo, Hospital Clinico San Carlos: P., Guerra, R., Biagioni, C., Gonzalez, R. A., Gomez deDiego, J. J., Mansson Broberg, L. Perez de Isla Sweden: Karolinska University Hospital: A., Sylve´n, C., Leblanc, K., Winter, R., Blomberg, P., Gunyeli, E., Ruck, A., Silva, C., Fo¨rstedt Switzerland: CardioCentro Ticino, J., Moccetti, Switzerland: T., Rossi, M., Pasotti, E., Petrova, I., Crljenica, C., Monti, C., Murzilli, R., Su¨rder, D., Moccetti, M., Turchetto, L., Locicero, V., Chiumiento, L., Maspoli, S., Mombelli, M., Anesini, A., Biggiogero, M., Ponti, G., Camporini, C., Polledri, S., Hill, G. Dolci United Kingdom: Kings College Hospital: J., Plymen, C., Amin Youssef, G., Mcdonagh, T., Drasar, E., Mijovic, A., Jouhra, F., Mcloman, D., Dworakowski, R., Webb, I., Byrne, J., and Potter, V.

Subjects
0301 basic medicine, Male, Cardiopoiesis, Cardiovascular disease, Disease severity, Marker, Precision medicine, Regenerative medicine, Stem cell, Target population, Adult, Aged, Double-Blind Method, Female, Heart Failure, Humans, Mesenchymal Stem Cell Transplantation, Middle Aged, Myocardial Ischemia, Prospective Studies, Treatment Outcome, Young Adult, Cardiology and Cardiovascular Medicine, Cell- and Tissue-Based Therapy, mesenchymal stem-cells, 030204 cardiovascular system & hematology, Cardiorespiratory Medicine and Haematology, outcomes, Fast-Track Clinical Research, Sudden cardiac death, 0302 clinical medicine, Ischemia, cardiovascular disease, Clinical endpoint, target population, CHART Program, Ejection fraction, bone-marrow, Heart Failure/Cardiomyopathy, 3. Good health, Cohort, Cardiology, Fast Track, disease severity, delivery, medicine.medical_specialty, precision medicine, Clinical Sciences, regenerative medicine, 03 medical and health sciences, cardiopoiesis, Internal medicine, medicine, Adverse effect, marker, disease, business.industry, medicine.disease, mortality, Confidence interval, Clinical trial, stem cell, Editor's Choice, 030104 developmental biology, predictors, Cardiovascular System & Hematology, Heart failure, business
Abstract

Altres ajuts: This work was supported by Celyad, SA (Mont-Saint-Guibert, Belgium). Celyad has received research grants from the Walloon Region (Belgium, DG06 funding). Cardiopoietic cells, produced through cardiogenic conditioning of patients' mesenchymal stem cells, have shown preliminary efficacy. The Congestive Heart Failure Cardiopoietic Regenerative Therapy (CHART-1) trial aimed to validate cardiopoiesis-based biotherapy in a larger heart failure cohort. This multinational, randomized, double-blind, sham-controlled study was conducted in 39 hospitals. Patients with symptomatic ischaemic heart failure on guideline-directed therapy (n = 484) were screened; n = 348 underwent bone marrow harvest and mesenchymal stem cell expansion. Those achieving > 24 million mesenchymal stem cells (n = 315) were randomized to cardiopoietic cells delivered endomyocardially with a retention-enhanced catheter (n = 157) or sham procedure (n = 158). Procedures were performed as randomized in 271 patients (n = 120 cardiopoietic cells, n = 151 sham). The primary efficacy endpoint was a Finkelstein–Schoenfeld hierarchical composite (all-cause mortality, worsening heart failure, Minnesota Living with Heart Failure Questionnaire score, 6-min walk distance, left ventricular end-systolic volume, and ejection fraction) at 39 weeks. The primary outcome was neutral (Mann–Whitney estimator 0.54, 95% confidence interval [CI] 0.47–0.61 [value > 0.5 favours cell treatment], P = 0.27). Exploratory analyses suggested a benefit of cell treatment on the primary composite in patients with baseline left ventricular end-diastolic volume 200–370 mL (60% of patients) (Mann–Whitney estimator 0.61, 95% CI 0.52–0.70, P = 0.015). No difference was observed in serious adverse events. One (0.9%) cardiopoietic cell patient and 9 (5.4%) sham patients experienced aborted or sudden cardiac death. The primary endpoint was neutral, with safety demonstrated across the cohort. Further evaluation of cardiopoietic cell therapy in patients with elevated end-diastolic volume is warranted.

Published
2017

29. P3585Comparison of 3 year outcomes between medical therapy and percutaneous revascularisation for surgically ineligible patients

Author

Ekmejian, A, primary, Lee, A, additional, Firoozi, S, additional, Sapontis, J, additional, Bhindi, R, additional, Hansen, P, additional, Ward, M, additional, Kaura, A, additional, Hill, J, additional, Dwokarowski, R, additional, MacCarthy, P, additional, Melikian, N, additional, Webb, I, additional, Shah, A, additional, and Byrne, J, additional

Published
2018
Full Text
View/download PDF

30. Comparison of 3-Year Outcomes Between Medical Therapy and Percutaneous Revascularisation for Surgically Ineligible Patients

Author

Ekmejian, A., primary, Lee, A., additional, Shetty, P., additional, Sapontis, J., additional, Firoozi, S., additional, Bhindi, R., additional, Hansen, P., additional, Ward, M., additional, Kaura, A., additional, Hill, J., additional, Dworakowski, R., additional, MacCarthy, P., additional, Melikian, N., additional, Webb, I., additional, Shah, A., additional, Byrne, J., additional, and Danson, E., additional

Published
2018
Full Text
View/download PDF

37. Fluorine Compounds, Inorganic, Halogens

Author

Webb I. Bailey and Andrew Joseph Woytek

Subjects
Bromine trifluoride, Chlorine trifluoride, Chemistry, Inorganic chemistry, chemistry.chemical_element, chemistry.chemical_compound, Iodine pentafluoride, Halogen, Oxidizing agent, polycyclic compounds, Chlorine, Fluorine, Organic chemistry, Compounds of fluorine
Abstract

There are eight known halogen fluorides, binary compounds of fluorine with chlorine, bromine, and iodine. The halogen fluorides are highly reactive, powerful oxidizing agents that exist as noncryogenic liquids, offering a storable liquid source of fluorine at low pressure. Properties are described. Chlorine trifluoride, bromine trifluoride, and iodine pentafluoride are available commercially. Chlorine trifluoride is used in the processing of nuclear fuels, bromine trifluoride as a chemical cutting agent for oil well pipe and tubing, and iodine pentafluoride as a fluorinating agent for organic compounds.

Published
2000
Full Text
View/download PDF

44. A phase III, randomized study of the investigational agent TAK-700 plus prednisone for patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC).

Author

Saad, F., primary, Akaza, H., additional, Eisenberger, M. A., additional, Nelson, J., additional, Scher, H. I., additional, Suzuki, K., additional, Wirth, M., additional, Webb, I. J., additional, Wang, J., additional, MacLean, D., additional, and De Wit, R., additional

Published
2011
Full Text
View/download PDF

50. A247 Bortezomib, Dexamethasone, Cyclophosphamide, Lenalidomide (VDCR) Has High Efficacy in First-Line MM

Author

Kumar, S, primary, Flinn, Ian, additional, Noga, S, additional, Hari, R, additional, Rifkin, R, additional, Callander, N, additional, Bhandari, M, additional, Wolf, J, additional, Gasparetto, C, additional, Krishnan, A, additional, Grosman, D, additional, Glass, J, additional, Sahovic, EA, additional, Shi, J, additional, Webb, I, additional, Richardson, PG, additional, and Rajkumar, SV, additional

Published
2009
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results